Renal Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
Condition: Clear Cell Renal Cell Carcinoma Intervention: Diagnostic Test: 68Ga-NY104 PET/CT Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials

68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Condition: Metastatic Clear Cell Renal Cell Carcinoma Intervention: Diagnostic Test: 68Ga-NY104 PET/CT Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials

68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Condition: Clear Cell Renal Cell Carcinoma Intervention: Diagnostic Test: 68Ga-NY104 PET/CT Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
Condition: Clear Cell Renal Cell Carcinoma Intervention: Diagnostic Test: 68Ga-NY104 PET/CT Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Condition: Metastatic Clear Cell Renal Cell Carcinoma Intervention: Diagnostic Test: 68Ga-NY104 PET/CT Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2023 Category: Research Source Type: clinical trials

A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Condition: Metastatic Renal Cell Carcinoma Intervention: Sponsor: Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 15, 2023 Category: Research Source Type: clinical trials